Best Grants for Digestive System Health and Diseases in Puerto Rico

The NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) invites proposals for high-risk, multi-center observational studies on diseases relevant to NIDDK's mission. Applicants are encouraged to consult with NIDDK staff and must complete planning activities before submission. Key deadlines for applications span from February 2025 to October 2026, with optional Letters of Intent due 30 days prior to full proposals.

The Small Grants for New Investigators program aims to enhance participation in health-related research by supporting new investigators from diverse backgrounds. This initiative encourages projects in the scientific areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Eligible applicants may receive funding for small research projects, promoting research independence and innovation while addressing the underrepresentation in biomedical research.

This funding opportunity invites innovative pilot studies focused on biological, behavioral, and social mechanisms related to HIV pathogenesis, aligning with NIDDK's mission and NIH HIV/AIDS research priorities. Topics may include exploring pathophysiological mechanisms of HIV comorbidities and coinfections, understanding HIV reservoirs in relevant tissues, and examining social determinants affecting health outcomes. Applications are due by 5:00 PM local time of the applicant organization.

Medtronic is a global leader in medical technology, dedicated to enhancing healthcare access and supporting the communities it serves. Through its Grants and Donations program, Medtronic provides financial assistance for medical education, independent conferences, and charitable events, emphasizing collaboration with healthcare stakeholders. The program aims to alleviate pain, restore health, and extend life, positively impacting millions of patients worldwide. For more information, visit Medtronic's FAQs on grants and donations.

The NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) invites applications for high-risk clinical trials that involve multiple centers and aim to change clinical practice or public health. Applicants are encouraged to submit Letters of Intent 30 days before the proposal deadline, with various deadlines set from February 2025 to October 2026. Planning activities must be completed before submission, and consultation with NIDDK staff is advised.

The Limited Competition Small Grant Program for NIDDK K01/K08/K23/K25 recipients offers funding opportunities for pilot studies and feasibility research. This program aims to support researchers transitioning to independent investigator roles by providing resources for small projects that can yield preliminary data for future R01 applications. Key deadlines for applications range from February 2025 through January 2028, with specific dates for standard, renewal, and AIDS-related applications.

The NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) supports innovative, hypothesis-driven clinical studies with a focus on diseases relevant to NIDDK. This initiative facilitates early peer review and assessment of study designs while providing essential support for operational documents. Applicants are encouraged to consult with NIDDK staff before submission to enhance the chances of success.

The Kenneth Rainin Foundation seeks to promote innovative research in Inflammatory Bowel Disease (IBD) by encouraging diverse perspectives from early career investigators and those underrepresented in science. The Innovator Awards do not require preliminary data and are evaluated based on the potential for innovation and scientific merit. Eligible researchers must hold advanced degrees and can apply for funding through their home institutions, fostering groundbreaking ideas that can transform IBD treatment and prevention.

The Stimulating Hematology Investigation: New Endeavors (SHINE) program aims to enhance nonmalignant hematology research aligned with the goals of the NIDDK, NIA, and NHLBI. It invites R01 grant applications focused on innovative and early translational hematology topics, fostering growth in this critical research area. Key deadlines for applications span from February 2025 to October 2027, allowing for both standard and renewal submissions.

The Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) program invites applications to enhance communication and collaboration among researchers in digestive and liver diseases. Funded by the NIDDK, DDRCCs focus on shared resources that foster productivity and innovative research ideas. Each center must revolve around a central theme aligned with the NIDDK's mission, ensuring effective research support while avoiding overlap with other NIH Institutes' funding areas.

The NIDDK is expanding its Gastroparesis Consortium into the Disorders of Gastrointestinal Interoception Consortium (DGIC) to explore various GI disorders linked to interoceptive processing. This initiative aims to include multiple Clinical Research Centers and a Scientific Data Research Center, focusing on multidisciplinary approaches to uncover mechanisms connecting GI function to symptoms. The effort seeks to identify biomarkers and novel therapeutic targets for future clinical trials, enhancing understanding and treatment of complex gastrointestinal conditions.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) aims to enhance understanding of inflammatory bowel diseases (IBD) through genomic research. By leveraging patient cohorts and advanced data science, the IBDGC seeks to identify genetic risk factors and develop predictive biomarkers for disease outcomes. This initiative will improve medical management and advance precision medicine for IBD patients, addressing the need for effective diagnostics and treatment strategies in this chronic condition.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Data Coordinating Center aims to enhance understanding of inflammatory bowel disease (IBD) by coordinating extensive genetic research. By leveraging diverse patient cohorts and advanced data science techniques, the center seeks to identify genetic risk factors, develop predictive biomarkers, and improve IBD patient management. This initiative will facilitate collaboration among various research centers and ensure efficient data collection and sharing to foster advancements in precision medicine for IBD.

The NIDDK Disorders of Gastrointestinal Interoception Consortium Clinical Centers (DGIC) aims to enhance understanding of gastrointestinal disorders by expanding the previous Gastroparesis Consortium's research scope. This initiative will include adult and pediatric conditions linked to impaired interoceptive processing, utilizing multidisciplinary approaches to uncover mechanisms connecting GI function to symptoms, identify biomarkers for treatment efficacy, and explore new therapeutic targets for future clinical trials.

The NIDDK Disease Research and Translational Core Centers (P30 Clinical Trial Optional) program invites applications to support innovative biomedical research focused on cystic fibrosis, diabetes, and other chronic diseases. These centers foster collaboration, provide essential resources, and mentor early-stage investigators, enhancing the research landscape. Funding will support pilot programs and access to shared services, ensuring efficient use of resources while promoting a robust scientific community dedicated to advancing health outcomes.

The NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34) aims to support high-risk, multi-center clinical studies by facilitating early peer review and assessment of study designs. This program helps in the development of necessary operational documents and essential elements for conducting hypothesis-driven studies focused on diseases relevant to NIDDK. Applications are due by 5:00 PM local time, and consulting with NIDDK staff is strongly encouraged.

The R01 grant program aims to address disparities in liver diseases and liver cancer in the United States. It supports multi-level intervention research targeting populations with significant health disparities. With deadlines spanning from February 2024 to June 2027, this initiative encourages innovative approaches to improve health outcomes in underserved communities, ultimately enhancing public health and reducing inequities in healthcare access and treatment.

The True Inspiration Awards, established by Chick-fil-A in 2015, recognizes nonprofit organizations that significantly impact their communities. In 2025, the program will distribute $6 million in grants, ranging from $30,000 to $350,000, to sixteen selected organizations. Categories include Caring for People, Caring through Food, Community, and Caring for our Planet, with a focus on educational initiatives, food security, housing services, and environmental stewardship, honoring the legacy of founder S. Truett Cathy.

Roche Corporate Donations and Philanthropy (CDP) focuses on impactful projects that foster sustainable development, engage employees, and leverage Roche's expertise. Their philanthropic efforts prioritize humanitarian, educational, environmental, and cultural initiatives, aiming to build stronger communities and support innovative projects. Eligibility is limited to local organizations, while ineligible projects include those with political or religious ties. The foundation strives to create a positive societal impact through collaboration and strategic partnerships.

The Research Foundation of the ASCRS offers the Limited Project Grant to support innovative research in colon and rectal surgery. With funding up to $25,000 for one year, this grant aims to foster investigator-initiated, hypothesis-driven projects conducted in the U.S. or Canada. Successful applicants may secure further funding from national agencies. ASCRS membership is required for principal investigators, ensuring a dedicated approach to advancing colorectal health and surgical techniques.

The Eugene Salvati, MD, Limited Project Grant, offered by the Research Foundation of the American Society of Colon and Rectal Surgeons, supports clinical research in colorectal surgery. This grant aims to honor Dr. Salvati's legacy by funding innovative projects that improve patient care. With a maximum funding of $25,000 for one year, it emphasizes investigator-initiated research conducted within the U.S. or Canada, encouraging collaboration among ASCRS members and adherence to ethical review board protocols.

The General Surgery Resident Research Initiation Grant aims to engage General Surgery Residents in research related to colorectal diseases. With an annual funding of $20,000, this grant supports both clinical and laboratory-based research. It is geared towards residents or recent graduates of approved General Surgery programs, prioritizing those with aspirations in Colon and Rectal Surgery. This initiative fosters innovative research to enhance patient care and surgical techniques in the field.

The Medical Student Mentored Summer Research Program offers medical students in the U.S. and Canada a unique opportunity to engage in a 10-week research experience under expert mentorship in pediatric gastroenterology, hepatology, or nutrition. With a stipend of $4000 paid in installments, this program is designed for students who have completed at least their first year of medical training. Preference is given to those seeking research experience between their first and second years.

The NASPGHAN Foundation/NASPGHAN George Ferry Young Investigator Development Award supports promising clinical, quality improvement, translational, or basic science research focused on gastrointestinal tract diseases, liver, pancreas, and nutritional disorders in children. Eligibility includes being a NASPGHAN member for at least two years, having a recent fellowship, and holding a junior faculty position. This award fosters innovative research to enhance pediatric gastroenterology and improve child health outcomes.

The Crohn's & Colitis Foundation/NASPGHAN IBD Young Investigator Award supports early-career researchers in inflammatory bowel disease (IBD). This three-year grant offers mentorship and funding up to $60,000 annually, plus additional support for research-related expenses. Eligible applicants must hold an MD or PhD, demonstrate relevant research experience, and commit at least 65% of their time to the project. The award also facilitates access to IBD Plexus resources, enhancing research capabilities in the field.

The NASPGHAN Foundation/APGNN Susan Moyer Research Grant supports impactful research and quality improvement initiatives aimed at enhancing nursing care for children with gastrointestinal and nutritional disorders. Grants ranging from $500 to $5000 are available for eligible Registered Nurses who are APGNN members. Awardees must present their findings at the NASPGHAN Annual Meeting and adhere to specific funding guidelines, including IRB approval and acknowledgment of support in publications.

American Gastroenterological Association

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, AGA represents members from around the globe who are involved in all aspects of the science, practice, and advancement of gastroenterology. The AGA Institute administers the practice, research, and educational programs of the organization.

AGA-Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease

This award provides funding for three years to early-career faculty (i.e., investigator, instructor, research associate or equivalent) working toward an independent career in inflammatory bowel disease (IBD) research.

Objective

The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for mentored research (i.e., a minimum of 50 percent effort dedicated to the proposed project). This award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research pertaining to inflammatory bowel disease.

Review all of the benefits AGA Research Scholar Award recipients are entitled to on the award policies page.

Application Requirements

• Maintain AGA membership throughout the three-year duration of the award.

• Applicants must self-assign their proposal to one of the following categories:
  • Clinical: Research involving direct contact with human subjects or using clinical data to address problems related to the prevention, diagnosis, treatment or outcome of human diseases (e.g., clinical epidemiology). This category also includes research related to health care delivery (e.g., health services, health IT).
  • Basic/Translational: Research with a primary goal of understanding basic biology or disease mechanisms. This category can involve animal subjects, cell culture, human biospecimens or human data as resources for laboratory- or informatics-based investigation.

• Resources allocated through this award are intended to support the career development of the applicant. The applicant must allocate a minimum of 50 percent effort to the proposed project.

• Applicants are required to have a sponsor and mentor for the award; one individual may serve in the capacity of both positions. A sponsor (typically a division chief or department chair) is an individual who takes responsibility for the quality assessment of the proposed research project, the quality of the research environment within which the project will be undertaken, and the experience and expertise of the principal investigator and other key researchers involved. A mentor will supervise the principal investigator’s research activities ensuring timelines and deliverables and will work with the applicant to create a research career development plan.

• The intent of this award is to foster the scientific independence of junior investigators. Applicants whose research activities become incorporated into a grant application from a senior mentor will need to delineate clearly the scientific and experimental distinctions between their respective programs. This requirement applies both to pending applications submitted prior to review of this award and to applications submitted during the term of the RSA. It must also be clearly stated how the work submitted by the applicant is that of the applicant and not that of the senior mentor(s).

• A complete research facilities and resources form must be submitted.

• Biographical sketches for the applicant, mentor and other key personnel must be submitted.

• Applicants resubmitting a revised application from a prior cycle must include a resubmission report describing responses to reviewer feedback and other major changes since the most recent past submission.

• Upon notification of receipt of this award, the recipient must provide institutional approval from the appropriate committee(s) for use of human subjects or animals. If approval is not necessary, then the recipient must provide documentation from the appropriate regulatory committee.

• Recipients must submit scientific and financial progress reports to AGA annually and final reports 60 days after the end date of the award period. Report templates and instructions are provided to awardees at the time of acceptance. Second and third year funding are contingent upon the submission and accuracy of this documentation.

• All publications, presentations, abstracts, and patent applications arising from work funded by this program must acknowledge support of the AGA–Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease.

• Additional pre-award policies are available on the Research Award Policies page.

Award Overlap

• At the time of application submission, applicants may not hold, or have held, an NIH K01, K08, K23, K99, R00, R01, R21, R29, Veterans Affairs Career Development Award or any award with similar objectives from non-federal sources (e.g., the American Liver Foundation, Crohn’s and Colitis Foundation of America, Robert Wood Johnson Foundation).

• Applicants who have held a K12 or KL2 in the past are eligible to apply. Applicants with an active K12 or KL2 may apply in the final year of their active K12 or KL2 so long as the award will end before the Research Scholar Award term begins.

• If a applicant is granted the award and notified of a comparable award from another agency prior to the first payment of this award, then the recipient must select one of the two awards (i.e., the recipient may not retain both awards).

• If the recipient is notified that a comparable award has been granted after the first payment of this award, then the recipient may retain up to 50 percent of the remainder of his or her AGA award. AGA must be notified by the recipient via email within two weeks of receiving notification of additional funding.